Status:
COMPLETED
Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis
Lead Sponsor:
Fondation Hôpital Saint-Joseph
Conditions:
Tuberculosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Linezolid, primary treatment for MDR-TB combination therapy anti. Until it is the dose of 600 mg x1 / day, rather sensible for most patients is more, which was unanimous. It is true that if a dosage i...
Detailed Description
Primary objective : Determination of the AUC / MIC and% T\> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently...
Eligibility Criteria
Inclusion
- Age \>18 years
- MDR-TB / XDR
- Treated by Linezolide per os at total daily dose of 600 mg-treatment started for\> 7 days
- BMI \<35 kg / m²
Exclusion
- Age \<18 years
- Treatment By Linezolide PO at a dose\> or \<600mg / d or I.V.
- Treatment Started since \<7 days (Plock, 2007)
- Insufficient moderate renal or severe / dialysis
- BMI\> 35 kg / m²
Key Trial Info
Start Date :
November 4 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2018
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT02778828
Start Date
November 4 2015
End Date
December 31 2018
Last Update
February 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanatorium du Petit Fontainebleau Centre Médical de Bligny
Briis-sous-Forges, Essonne, France, 91640